May 2 |
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
|
Apr 25 |
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Apr 25 |
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
|
Apr 6 |
OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago
|
Apr 4 |
Optinose to Present at the Needham Virtual Healthcare Conference
|
Mar 16 |
OptiNose granted FDA nod to expand labeling for sinusitis therapy
|
Mar 15 |
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
|
Mar 10 |
US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
|
Mar 8 |
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript
|
Mar 8 |
OptiNose Full Year 2023 Earnings: EPS Beats Expectations
|